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Abstract
Background: The development of effective cancer vaccines still remains a challenge. Despite the crucial role of
plasmacytoid dendritic cells (pDCs) in anti-tumor responses, their therapeutic potential has not yet been worked out. We
explored the relevance of HLA-A*0201 matched allogeneic pDCs as vectors for immunotherapy.
Methods and Findings: Stimulation of PBMC from HLA-A*0201
+ donors by HLA-A*0201 matched allogeneic pDCs pulsed
with tumor-derived peptides triggered high levels of antigen-specific and functional cytotoxic T cell responses (up to 98%
tetramer
+ CD8 T cells). The pDC vaccine demonstrated strong anti-tumor therapeutic in vivo efficacy as shown by the
inhibition of tumor growth in a humanized mouse model. It also elicited highly functional tumor-specific T cells ex-vivo from
PBMC and TIL of stage I-IV melanoma patients. Responses against MelA, GP100, tyrosinase and MAGE-3 antigens reached
tetramer levels up to 62%, 24%, 85% and 4.3% respectively. pDC vaccine-primed T cells specifically killed patients’ own
autologous melanoma tumor cells. This semi-allogeneic pDC vaccine was more effective than conventional myeloid DC-
based vaccines. Furthermore, the pDC vaccine design endows it with a strong potential for clinical application in cancer
treatment.
Conclusions: These findings highlight HLA-A*0201 matched allogeneic pDCs as potent inducers of tumor immunity and
provide a promising immunotherapeutic strategy to fight cancer.
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Introduction
The development of effective vaccines for cancer treatment
represents a major public health issue [1]. Because cytotoxic T
lymphocytes (CTL) are able to recognize and lyse malignant cells,
many therapeutic trials have been designed to potentiate CTL
responses. Myeloid dendritic cells (mDC)-based vaccines succeeded
in inducing specific T cells in patients but without sufficient clinical
efficacy [2,3]. Adoptive cellular transfer of anti-tumor effector T cells
amplified ex-vivo from TIL induced objective tumor regression [4,5],
but the complexity of this strategy has hindered wide development.
Therefore, there is a strong need for novel immunotherapeutic
strategies to overcome the limitations of current protocols.
Up to now, the induction of specific T cell responses for both
adoptive and active immunotherapeutic strategies has been based
on mDCs [6–8]. Plasmacytoid dendritic cells (pDC) are however
key players in immunity [9,10] with a role in tumor-specific
immune responses [11]. pDCs differ from mDCs in many aspects
such as TLR expression, migration profile and immune responses
triggering. pDC are also capable of antigen capture, processing
and presentation [12–15]. Antigen-pulsed pDC can stimulate
specific primary (MelA) and memory (Flu) autologous CD4 and
CD8 T cell immune responses in vitro [16–19] and prime
functional T cell responses in vivo as shown after vaccination of
mice with CpG or virus-activated pDC [20–21]. pDC are found
within many tumors in humans [22–26], where they are thought
to be immature, tolerogenic or associated with poor prognosis.
However, in melanoma, pDC activation by TLR-L could trigger
potent anti-tumor effects. In mice, imiquimod application (TLR7-
L) [27] or intratumoral injection of CpG (TLR9-L) [28] reversed
the functional inhibition of pDC, thereby promoting tumor
regression. Moreover local CpG administration in melanoma
patients induced the recruitment and activation of pDC in sentinel
lymph nodes [29] and subsequent tumor-specific CD8 T cells
associated with clinical benefit [30]. The potential of pDC in
generating effective tumor-specific immune responses has also
been demonstrated in a mouse model [31]. pDC-based approach-
es and TLR agonists [32] are therefore promising for the
treatment of human cancer.
Tumor antigens usually trigger weak responses. In contrast,
allogeneic responses directed against non-self MHC are extremely
potent. Interestingly, the allogeneic response mediated by MHC
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10458Figure 1. HLA-A*0201 matched allogeneic pDCs induce highly effective tumor-specific T cell responses from HLA-A*0201
+ healthy
donors’ PBMC in vitro. (A,B) Autologous or allogeneic HLA-A*0201
+ primary pDC sorted from the blood of healthy donors were pulsed with MelA
peptide and used to stimulate HLA-A*0201
+ PBMC. The specific T cell response was analyzed at d7 by tetramer labelling. (A) Percentage of MelA
specific T cells (gated on CD8+ T cells). One representative experiment is shown. (B) Amplification of the absolute number of specific T cells from d0
to d7 (4 independent experiments performed with 3 different donors). (C,D) allogeneic HLA-A*0201
+ PBMC from healthy donors were stimulated with
the irradiated peptide-loaded HLA-A*0201
+ pDC line and weekly restimulated in the presence of IL2. Specificity of the T cells was determined by
tetramer labelling and flow cytometry analysis. (C) Representative dotplots gated on CD8+ T cells (left panel) and percentages (right panel) of MelA
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induction [33,34] as already shown with viral peptides [35] and
tumor regression following allogeneic skin graft [36]. Allogeneicity
could therefore be exploited to promote immunogenicity towards
tumor antigens [37] when considering a partial HLA match
between the vaccine and the patient, further referred to as HLA
matched allogeneicity.
Because pDCs play a fundamental role in triggering T cell
responses, their use could be promising as new immunotherapeutic
strategies. However, the use of autologous pDC for cancer
immunotherapy is difficult because of the scarcity of these cells
[38] and the possible functional alteration of pDCs harvested from
tumor-bearing patients. We therefore explored the potential of
HLA-A*0201 matched allogeneic pDC to induce HLA-A*0201-
restricted anti-tumor immunity. We used a unique human pDC
cell line (GEN) established from leukaemic HLA-A*0201
+ pDC
with phenotypic and functional features closed to primary pDCs
[39,40,41]. The strategy consisted of using the peptide-loaded
pDCs to induce HLA-A*0201-restricted antigen-specific CTL. We
demonstrate here using tumor and viral model antigens the
potential of the irradiated peptide-pulsed human HLA-A*0201
matched allogeneic pDC line (GENiusVac) in vitro, its therapeutic
efficacy in vivo in humanized mice, and its clinical relevance ex-
vivo with melanoma patients’ cells. Our findings highlight HLA-
A*0201 matched allogeneic pDCs as potent inducers of anti-tumor
immunity and provide a promising new immunotherapeutic
strategy to fight cancer.
Materials and Methods
Cell lines and reagents
Cultures were performed in RPMI 1640 Glutamax supple-
mented with 1% non-essential amino acids, 1 mM sodium
pyruvate (Sigma), 100 mg/ml gentamycin and 10% FCS (all from
Invitrogen unless notified). Melanoma line Me275 was provided
by Pr J-C Cerottini (Ludwig Institute for Cancer Research,
Epalinges, Switzerland). Melanoma lines COLO829 and A375,
T2 and K562 lines were purchased from ATCC (LGC Standards,
Molsheim, France). Melanoma line Mel89 was generated in our
laboratory (Figure S1). Anti-human CD45, CD3, CD8 Abs were
purchased from Beckman Coulter. Anti-HLA-A2 Abs were
purchased from BD Biosciences and anti- human MelA from
Sigma.
Peptides and tetramers
We used the following viral- and tumor-derived HLA-A*0201
restricted peptides (NeoMPS) and the corresponding iTag HLA-
A*0201 tetramers (Beckman Immunomics): MelA26–35 (ELAGI-
GILTV), GP100209–217 (IMDQVPFSV), tyrosinase369–377
(YMDGTMSQV), MAGE-3271–279 (FLWGPRALV), FluM158–66
(GILGFVFTL), CMVpp65495–503 (NLVPMVATV).
PBMC, pDC line, primary pDC isolation and mDCs
generation
Human PBMC were obtained from HLA-A*0201
+ healthy
donors by Ficoll-Hypaque density gradient centrifugation (Euro-
bio). The human pDC line GEN2.2 was cultured as previously
described [39]. Primary pDC were isolated from the blood of
HLA-A*0201
+ healthy donors. DCs were first enriched by
depletion of unwanted cells using the Pan DC pre-enrichment
kit (StemCell). Recovered cells were either submitted to BDCA4+
selection (Miltenyi) or labelled with a Lineage cocktail, CD123,
HLA-DR and CD11c antibodies (BD) and sorted on a BD
FACSAria on the basis of CD123 and HLA-DR expression and
lack of Lin and CD11c markers. The purity of pDC after sort was
over 98%. mDCs were differentiated from blood monocytes using
500 U/ml GM-CSF and 10 ng/ml IL-4 (TEBU Prepotech,
France) for 6 days. This study was conducted under a procedure
approved by the French Blood Agency Institutional Review
Board. All donors signed informed consent forms.
Melanoma patient samples
Samples were obtained from stage I to IV HLA-A*0201
melanoma patients who signed informed consent forms. We used
extra material that was not required for patients’ diagnosis or
analysis and didn’t required supplementary procedures. Therefore
in accordance with the French regulation, no ethic approval was
required but information and signed consent of the patients.
Clinical parameters are shown in Table S1. Blood samples were
obtained from 12 patients and PBMC purified by gradient density.
Fresh tumor samples were obtained from 6 patients who
underwent surgery for in-transit metastasis. Samples were
dilacerated and digested in 2 mg/ml collagenase D (Roche
Diagnostics) 20 U/ml DNase (Sigma). Then tumor cells were
isolated from the cell suspension by adherence and TIL enriched
from the non-adherent fraction by density gradient.
Specific T cell response induction in vitro
GEN cells were first loaded with one or several peptide(s) of
interest. Briefly, cells were washed 3 times with serum-free RPMI
and resuspended at 1.10
6 cells/ml. b2-microglobulin (0.1 mg/ml
final) (Sigma) and peptide(s) (1–10 mM final) (NeoMPS) were
added. After 3 hours of incubation at 37uC, cells were washed
twice, irradiated with 30Gy and resuspended at 2.10
5 cells/ml in
RPMI with 10% FCS. Peptide-loaded GEN were then co-cultured
with semi-allogeneic HLA-A*0201 PBMC at a 1:10 ratio in RPMI
+ 10% FCS for at least 7 days. Cultures were weekly restimulated
with peptide-loaded GEN and 200 U/ml IL-2 (Proleukine;
Chiron). In some experiments, unstimulated primary pDCs or
mDCs matured with LPS (1 mg/ml) were used following the same
conditions. In some experiments blocking anti-IFNa (50.000 U/
ml) and anti-IFNb (25.000 U/ml) antibodies (PBL Medical
laboratories) or control goat IgG were added at day 0 and day 2
of culture. Specific CD8 T cell responses were measured by
tetramer labelling of PBMC initially and at different steps of the
culture. Cells were resuspended in HBSS with 2% FCS, stained
with CD45 FITC, iTAg HLA-A*0201 tetramer PE, CD3 PC7,
CD8 APC antibodies and analyzed by flow cytometry analysis
using a FACSCalibur and Cell Quest software (Becton Dickinson).
To determine initial tetramer levels, at least 1–2.10
6 events were
acquired.
In vitro functional assays
IFNc secretion and CD107 expression by tetramer+ CD8
T cells. T cells were first labelled with iTAg HLA-A*0201
tetramer PE for 30 min at RT, washed and restimulated with
peptide-pulsed T2 cells (10:1 ratio) for 5 h30. For IFNc secretion,
1 ml/ml brefeldin A (BD Biosciences) was added for the last 3 h.
tetramer
+ T cells in the culture initially and at different time points after stimulation with the pDC line loaded with MelA peptide. Flu tetramer was
used as control. (D) Representative dot plots gated on CD8+ T cells (left panel) and percentages of tetramer
+ CD8+ T cells obtained at days 7, 14 and
20 of the culture towards MelA (n=18), GP100 (n=16), TYR (n=16) and MAGE-3 (n=16) tumor antigens.
doi:10.1371/journal.pone.0010458.g001
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PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10458Figure 2. The tumor-specific T cells primed by the HLA-A*0201 matched allogeneic pDC line in vitro exhibited functional antigen-
and HLA-A*0201-specific activity. (A) MelA-specific T cells induced by the pDC line secrete IFNc and express CD107 on the surface upon specific
restimulation. Cells from the culture (day 14) were submitted to tetramer labelling and restimulated with T2 cells pulsed with a relevant or control
peptide. IFNc production was assessed by intracellular staining and CD107 expression by adding anti-CD107a+b antibodies during the restimulation.
Dotplots are gated on tetramer
+ CD8+ T cells. Representative of 8 experiments performed with 3 donors at day 8–40 of the culture. (B) MelA-specific T
cells induced by the pDC line are cytotoxic. T cells were selected from the culture and submitted to a
51Cr release assay using peptide-loaded T2 cells
and melanoma tumor cells as targets. Representative of 8 experiments performed with 4 donors at d13–40 of the culture. (C,D) IFNc secretion and
CD107 expression were assessed as described in (A) after three stimulations of PBMC and analyzed on the tetramer
+ CD8+ T cells (white bars) and on
the non-specific tetramer
- CD8+ T cells (grey bars) and CD4+ T cells (black bars) upon restimulation with peptide-pulsed T2 or GEN cells (4
experiments for each condition).
doi:10.1371/journal.pone.0010458.g002
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APC antibodies and submitted to IFNc intracellular staining (BD
Biosciences). For CD107 detection, anti-CD107a and CD107b
FITC antibodies (10 ml/1.10
6 cells) (BD Biosciences) were added
in the medium at the beginning of the restimulation in presence of
Golgi STOP (0.67 ml/ml) for the last 4 h. Cells were then labelled
with anti-CD3 PC7 and anti-CD8 APC antibodies. IFNc and
CD107 staining were analyzed on the tetramer
+ CD8+ T cells,
tetramer
- CD8+ T cells and CD4+ T cells.
Cytotoxicity assay. Antigen-specific cytotoxic activity was
measured by performing a standard
51Cr release assay. Effector T
cells were sorted from the co-culture using an EasySep human T
cell enrichment kit (Stem Cell). Target cells (peptide-pulsed T2
cells, K562, allogeneic or autologous tumor cells) were labeled
with 50 mCi for 1 hour at 37uC, washed 3 times and plated with
effector T cells at the indicated E:T ratio in round bottom 96-well
plates. After 4 hours of incubation, radioactivity was measured on
30 ml of supernatants on a microplate scintillation counter Top
Count NXT (Perkin Elmer). The mean of triplicate measure-
ments was expressed as a percentage of specific lysis using the
formula: (sample release – spontaneous release)/(maximal release
– spontaneous release) 6100.
In vivo functional assays in humanized mice
NOD-SCID b2m
-/- immunodeficient mice (NOD.Cg-
Prkdc
SCIDb2m
Tm1Unc/J) were purchased from Jackson Immu-
noResearch Laboratories (Bar Harbor, USA) and bred at the
Plateforme de Haute Technologie Animale (PHTA, La Tronche,
France). For active therapy experiments, HuPBL mice were
constructed by transplanting intraperitoneally (ip) 50.10
6 PBMC
from healthy donors into sublethally irradiated NOD-SCID
b2m
-/- mice (120–150 cGy). Mice were further vaccinated with
5.10
6 irradiated peptide-pulsed GEN cells by ip or sc routes once
a week. Response to vaccination was analysed at different time
points in blood, peritoneal lavage, spleen and lymph nodes.
Organs were digested 30 min at 37uC with 2 mg/ml collagenase
D (Roche Diagnostics). Resultant cell suspensions were washed
with HBSS + 2% FCS, stained using the following anti-human
antibodies (CD45 FITC, iTAg HLA-A*0201 tetramer PE, CD3
PC7, CD8 APC) and submitted to flow cytometry analysis. To
assess therapeutic efficiency, 1.10
6 human tumor cells were
implanted subcutaneously into the flank of the humanized mice
either 5 days after (prophylactic) or 4 days before (therapeutic) the
first vaccination. Vaccination was repeated every week. Tumor
size was monitored every 2–3 days and tumor volume calculated
using the formula: (short diameter)
26 long diameter/2. To
analyse specific T cells at the tumor site and in DLN, tissues were
digested as previously described and cell suspensions were
submitted to tetramer labelling and flow cytometry analysis. All
in-vivo experiments have been approved by the Regional
Committee for Animal Ethic Rhone-Alpes (CREEA) affiliated
to the CNRS.
Statistical analysis
The statistical analyses were performed by using Mann-Whitney
non parametric U test and unpaired t test using Prism software.
Results
Human HLA matched allogeneic pDCs induce antigen-
specific T cell responses from healthy donor PBMC with a
strong efficacy in vitro
To investigate the potential of HLA matched allogeneic pDC in
antigen-specific T cell responses induction, we compared the
ability of peptide-loaded primary pDC sorted from healthy donors’
blood to induce specific T cell responses in autologous and
allogeneic HLA-A*0201-matched settings. pDC led to a signifi-
cantly higher specific T cell induction in HLA-A*0201 matched
allogeneic settings compared to autologous conditions (amplifica-
tion of the absolute number of MelA-specific T cells in 7 days:
35.668.9 vs 17.968.7, mean6SEM, p=0.02) (Figure 1A and 1B,
four experiments performed with three different donors). As the
scarcity of primary pDC prevents their wide therapeutic use, we
used the human pDC cell line (GEN) established from leukaemic
HLA-A*0201
+ pDC as a source of HLA-A*0201 matched
allogeneic pDCs. To assess whether the irradiated HLA-
A*0201
+ pDC line can induce specific T cell responses like
primary pDC in vitro, allogeneic HLA-A*0201
+ PBMC from
healthy donors were stimulated with the irradiated peptide-loaded
GEN cells. For both tumor (MelA) and viral (Flu)-derived peptides,
we obtained a massive amplification of specific T cells after only 7
days of culture as detected by tetramer labelling (Figure 1C, Figure
S2). This induction was further enhanced by serial stimulations
every 7 days with the peptide-loaded pDC line, in combination
with IL-2. We routinely obtained 5–25% of tetramer
+ CD8 T cells
after 7 days, 40–60% after 15 days, and up to 98% after 40 days
(Figure 1C). Such high responses were reproduced with cells from
14–20 healthy donors and with various melanoma tumor-derived
antigens such as MelA, GP100, TYR, MAGE-3 (Figure 1D) as
well as virus-derived antigens (Figure S2). Tumor-specific
tetramer
+ T cell responses reached averages of 22% for MelA
(range 2–60%), 0.3% for GP100 (range 0–3%), 1.2% for TYR
(range 0–8%) and 0.84% for MAGE-3 (range 0–4%) in 20 days.
Multi-specific responses were also induced using GEN cells loaded
with several different peptides (not shown). Thus, HLA matched
allogeneic primary pDCs or the pDC line elicit strong primary and
memory antigen-specific T cell responses in vitro from healthy
donors.
The specific T cells induced by HLA matched allogeneic
pDC exhibited in vitro functional HLA-restricted activity
We further examined the functionality of the specific T cells
induced by the HLA-A*0201 matched allogeneic pDC line. We
first analyzed the ability of tumor-specific T cells to secrete IFNc
and express CD107 upon restimulation. When co-cultured with
Figure 3. Vaccination with the peptide-loaded HLA-A*0201 matched allogeneic pDC line elicits strong antigen-specific T cell
responses in humanized mice. (A-B) Immunodeficient NOD-SCIDb2m
-/- mice were reconstituted intraperitoneally with 50.10
6 human HLA-
A*0201
+ healthy donors’ PBMC and vaccinated by the same route with 5.10
6 irradiated peptide-loaded GEN cells. Specific T cell induction was
analyzed at the injection site (lavage), in the circulation (blood) and lymphoid organs (spleen, LN) by tetramer labelling of human T cells in cell
suspensions. (A) Vaccination with peptide-loaded GEN cells induced specific T cell responses in vivo. Representative dot plots of tetramer labeled T
cells induced after a single vaccination with peptide-loaded GEN cells in different organs at day 8 for anti-viral vaccine (Flu, CMV) and day 10 for anti-
tumor vaccine (MelA) (gated on CD8
+ T cells). One mice per group is shown. Initial levels of specific T cells within PBMC were 0.04%, 0.14% and
0.003% respectively. (B) Levels of specific T cells before (day 0) and after vaccination with GEN loaded with FluM1 (n=22 mice, 4 donors, 1 vaccine),
CMVpp65 (n=18 mice, 2 donors, 1 vaccine) and MelA (n=38 mice, 4 donors, 2–3 vaccines) peptides at the indicated times in different organs. Each
dot represents one vaccinated HuPBL mice (bars at mean).
doi:10.1371/journal.pone.0010458.g003
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expressed CD107 in the presence of the relevant but not control
peptide (Figure 2A). We obtained within tumor-reactive T cells
averages of 25% IFNc
+ tetramer
+ CD8 T cells upon specific
restimulation compared to 5% under control conditions
(p=0.007), and 50% CD107
+ tetramer
+ CD8 T cells upon
specific restimulation compared to 24% under control conditions
(p=0.02) (data not shown). We next tested their cytotoxicity by
performing
51Cr release assay using peptide-loaded T2 cells and
melanoma tumor lines as targets. MelA-specific T cells exhibited a
strong cytotoxic activity towards T2 cells loaded with the relevant
but not with control peptide (Figure 2B). We obtained 88% of
specific killing versus 13% under control conditions (mean of 8
experiments, p,0.001) (not shown). In addition, MelA-specific T
cells were able to lyse HLA-A*0201
+MelA
+ (Me275) but neither
HLA-A*0201
+MelA
- (A375) nor HLA-A*0201
-MelA
+
(COLO829) melanoma tumor cells (Figure 2B, Figure S1)
demonstrating the HLA-A*0201-restriction and antigen specificity
of this activity. Furthermore, this lysis was inhibited by EGTA-
MgCl2 or by CD8 T cell depletion (not shown), which together
with CD107 surface expression upon specific restimulation,
suggests a mechanism involving cytolytic granule exocytosis from
CD8 T cells. Such functional capacities were observed with T cells
taken at different timepoints of the 7–40 day culture. Similar
analysis performed with virus-specific T cells demonstrated the
capacity of Flu tetramer
+ T cells to secrete IFNc and express
CD107 upon specific restimulation, and their cytotoxic properties
(Figures S3A and S3B). Importantly, we observed only a minor
allogeneic response induction as attested by the poor activation of
non-specific tetramer
– CD8+ T cells and CD4+ T cells towards
GEN cells. This was observed after one stimulation (Flu response)
(Figure S3C and S3D) but also after repeated stimulations with the
pDC line (MelA response), by measuring IFNc-secreting
(Figure 2C) and CD107-expressing T cells (Figure 2D) upon
restimulation with T2 or GEN cells. We also observed the absence
of the tetramer
+ T cell activity towards GEN cells loaded with an
irrelevant peptide. Thus, the pDC line elicits fully functional
antigen-specific T cells with minor bystander allogeneic responses.
The peptide-loaded HLA matched allogeneic pDC line
elicits strong in vivo antigen-specific T cell responses in
humanized mice
The use of HLA matched allogeneic pDCs as a vaccine
requires induction of antigen-specific T cell responses in vivo.
Therefore we evaluated the vaccine potential of the pDC line in a
humanized mouse model [42] constructed by xenotransplanting
human PBMC into immunodeficient NOD-SCIDb2m
-/- mice
(HuPBL SCID model). Twenty four hours after intraperitoneal
transfer, human CD45
+ haematopoietic cells were found at the
injection site but also in the circulation and lymphoid organs (not
shown). A single intra-peritoneal injection of the irradiated
peptide-loaded HLA-A*0201 matched allogeneic pDC line
induced strong antigen-specific T cell responses towards viral
(FluM1, CMVpp65) and tumor (MelA) antigens in HuPBL mice
(Figure 3A). Human tetramer
+ CD8 T cells were found not only
at the site of immunization (peritoneal lavage) but also in the
circulation (blood) and lymphoid organs (spleen, lymph nodes)
(Figure 3A). We then evaluated whether several weekly injections
of the peptide-pulsed pDC line could enhance the level of the
response. Interestingly, viral antigen (Flu) induced a high
response that peaked 7 days after the first vaccine and decreased
afterwards, whereas response to tumor antigen (MelA) kept
increasing upon subsequent restimulations (Figure S4). Within all
vaccinated HuPBL mice (n=22, 18 and 38) reconstituted with
human PBMC (baseline levels of tetramer+ CD8+ T cells were
0.11% (FluM1), 0.12% (CMVpp65) and 0.01% (MelA) tetramer
+
T cells) levels of specific T cells recovered in the different organs
ranged from 0.7 to 1.9% for FluM1, 1.1 to 5.9% for CMVpp65,
and 0.2 to 1% for MelA (Figure 3B). Thus, the peptide-pulsed
pDC line elicits strong and widespread antigen-specific T cell
responses in vivo.
Vaccination with the peptide-loaded HLA matched
allogeneic pDC line protect humanized mice from tumor
progression in both prophylactic and therapeutic
settings
We next investigated the therapeutic potential of this strategy in
humanized mice further engrafted with human tumor. NOD-
SCIDb2m
-/- mice were reconstituted intra-peritoneally with
human HLA-A*0201
+ PBMC and weekly vaccinated subcutane-
ously with irradiated peptide-pulsed GEN cells before or after
being challenged with melanoma tumor cells. In a prophylactic
setting, injection of HuPBL mice with MelA-loaded GEN cells,
compared to Flu-loaded GEN cells, inhibited HLA-
A*0201
+MelA
+ tumor growth (Me275) in five independent
experiments (tumor size at day 27=12 vs 77 mm
3,p ,0.0001)
(Figure 4A and 4C). By contrast, the growth of HLA-
A*0201
-MelA
+ (COLO829) and HLA-A*0201
+MelA
- (A375)
melanoma tumors was not affected after injection of MelA or
Flu-loaded GEN cells in three independent experiments
(Figure 4C), demonstrating the HLA-A*0201-restriction and
antigen specificity of the therapy. Moreover, the peptide-loaded
pDC also provoke protective immune responses against already
established tumors. Vaccination of tumor-bearing HuPBL mice
with MelA-loaded GEN cells inhibited tumor growth compared to
Flu-loaded GEN cells (tumor size at day 25=6 vs 36mm
3,
p=0.01) (Figure 4D-4F). Notably, tetramer
+ CD8+ T cells were
found at the tumor site and in the draining LN (Figures 4B and
4F), suggesting that the tumor-reactive T cells induced by the HLA
Figure 4. Vaccination with the peptide-loaded HLA-A*0201 matched allogeneic pDC line protect humanized mice from tumor
development both prophylactically and therapeutically. (A-C) Immunodeficient NOD-SCID b2m
-/- mice reconstituted intraperitoneally with
human HLA-A*0201
+ PBMC (HuPBL mice) were weekly vaccinated subcutaneously with irradiated MelA or Flu-loaded GEN cells and challenged 5 days
later with melanoma tumor cells in the flank. (A) Follow up of tumor progression. One experiment representative of 5. (B) Tetramer labelling of tumor
and draining LN cell suspensions from HuPBL mice vaccinated with MelA-loaded GEN cells showing the presence of MelA-specific T cells (gated on
CD8+ T cells). (C) The therapeutic effects of the vaccine are HLA-A*0201-restricted and antigen-specific. Comparative tumor size 27 days after
implantation of Me275, COLO829 and A375 melanoma cells into HuPBL mice vaccinated with MelA or Flu-loaded GEN cells (pool of 3 independent
experiments for each tumor type performed with 6 to 14 mice per group). (D-F) Immunodeficient NOD-SCID b2m
-/- mice reconstituted
intraperitoneally with human HLA-A*0201
+ PBMC (HuPBL mice) were first challenged with melanoma Me275 tumor cells in the flank and then
vaccinated subcutaneously with irradiated MelA or Flu-loaded GEN cells weekly starting 4 days later. (D) Follow up of tumor progression. One
representative experiment out of 2. (E) Comparative tumor size 25 days after tumor implantation (pool of 2 independent experiments, 8 mice/group).
(F) Tetramer labelling of tumor and draining LN cell suspensions from HuPBL mice vaccinated with MelA-loaded GEN cells showing the presence of
MelA-specific T cells (gated on CD8+ T cells).
doi:10.1371/journal.pone.0010458.g004
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10458Figure 5. The HLA-A*0201 matched allogeneic pDC line loaded with melanoma-derived peptides induces multi-specific T cell
responses ex-vivo from stage I-IV melanoma patients. PBMC (n=12) and TIL (n=6) obtained from stage I-IV HLA-A*0201
+ melanoma patients
were cultured with irradiated GEN cells loaded with MelA, GP100, TYR and/or MAGE-3 derived peptides and restimulated every 7 days. Percentages of
specific T cells were determined by tetramer labelling after culture of PBMC with single peptide-loaded GEN cells (A,B) and of TIL with GEN loaded
with a mix of the 4 peptides (C,D). Representative experiments with PBMC (A) and TIL (C) are shown at day 20 of the culture. Results from PBMC and
TIL cohorts are shown in (B) and (D) at days 0, 7, 14 and 20 of culture. For TYR (D), one patient was excluded due to an extremely intense response
(see Figure S5).
doi:10.1371/journal.pone.0010458.g005
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expression and the T cells were capable of killing tumor cells.
The HLA matched allogeneic pDC line loaded with
melanoma-derived peptides induces multi-specific and
highly functional T cell responses ex-vivo from stage I-IV
melanoma patients
We next investigated the relevance of this strategy in cancer
patients. We tested the capacity of the peptide-pulsed pDC line to
trigger ex-vivo tumor-specific responses from PBMC and tumor-
infiltrating lymphocytes (TIL) isolated from stage I-V HLA-
A*0201
+ melanoma patients (Tables S1 and S2). Weekly
stimulations of patients’ PBMC with the pDC line pulsed either
with MelA, GP100, TYR or MAGE-3 peptide led to the massive
amplification of specific CD8+ T cells for at least 2 out of 4
melanoma antigens (Figures 5A and 5B). The tumor-specific
tetramer
+ CD8 T cell responses reached averages of 23% for
MelA (range 0.4–62%), 1.2% for GP100 (range 0.05–3.5%), 0.3%
for TYR (range 0.01–2.5%) and 0.2% for MAGE-3 (range 0.03–
0.72%) after 20 days (baseline tetramer+ CD8+ T cells ranged
from 0.02 to 0.03% at d0). One patient was excluded from the
analysis due to an extremely intense response (85% tetramer
+ T
cells at day 14) towards TYR (Figure S5). Furthermore, repeated
stimulations of patients’TIL with the pDC line pulsed with a mix
of the 4 melanoma peptides led to the massive amplification of
specific T cells for at least 3 antigens (Figures 5C and 5D). Tumor-
specific tetramer
+ CD8 T cell responses reached averages of 39%
for MelA (range 12–59%), 7.4% for GP100 (range 0.2–24%),
0.3% for TYR (range 0.05–1.2%) and 1.1% for MAGE-3 (range
0.1–4.3%) after 20 days with baseline levels format day 0 1.7, 0.2,
0.05 and 0.3%, respectively. The tumor-specific T cells induced
from both PBMC (Figure 6A) and TIL (not shown) secreted IFNc
when co-cultured with T2 cells loaded with the relevant but not
with a control peptide. We obtained a mean of 42% of IFNc
+
tetramer
+ CD8 T cells upon specific peptide restimulation
compared to 11% in control conditions (n=12, p=0.0002, data
not shown). Furthermore, these T cells exhibited a strong cytotoxic
activity towards T2 cells loaded with relevant but not with control
peptides and allogeneic melanoma tumor cells in an HLA-
A*0201-restricted and antigen-specific manner (Figure 6B). Strik-
ingly, after stimulation with the pDC line loaded with a mix of four
melanoma-derived peptides, TIL acquired the ability to lyse
autologous tumor cells but not CD45
+ hematopoietic cells from
the patient (Figure 6C). When comparing the killing capacity of
unstimulated and stimulated TIL, the pDC line greatly enhanced
their cytotoxic activity towards peptide-loaded T2 cells, semi-
allogeneic melanoma tumor lines and autologous tumor cells
(Figure 6D). Thus, the HLA- matched allogeneic pDC line loaded
with melanoma-derived peptides induces multi-specific and highly
functional ex-vivo T cell responses from stage I-IV melanoma
patients.
The HLA matched allogeneic pDCs are more potent at
inducing tumor-specific T cells than conventional
autologous or HLA matched allogeneic mDCs
We next compared the T cell stimulatory capacity of the pDC
line against conventional mDCs in autologous and semi-allogeneic
settings. HLA-A*0201
+ PBMC from healthy donors were
stimulated with irradiated peptide-loaded GEN cells, HLA-
A*0201
+ allogeneic mDCs or autologous mDCs. The virus-
specific (FluM1) and tumor-specific (MelA) responses elicited
respectively after a single or three stimulations were higher when
using GEN cells compared to allogeneic or autologous mDCs
(Figure 7A-7D). Similarly, stimulation of TIL from melanoma
patients with GEN cells led to a more potent induction of tumor-
specific T cells than semi-allogeneic mDCs in respect to both
tetramer+ T cell percentage (Figures 8A and 8B) and fold increase
in absolute number of specific T cells (Figure 8C). Notably, the
pDC line elicited specific T cells with better functional qualities, as
assessed by more potent CTL activity towards autologous tumor
cells from melanoma patients, compared to the T cells induced by
conventional HLA matched allogeneic mDCs (Figures 8D and
8E). Thus, the induction of specific T cell responses by the pDC
line is much more potent compared to that elicited by autologous
or HLA matched allogeneic myeloid DCs.
In order to investigate the mechanism of the high efficiency of
the pDC line, we analysed changes in the activation level of the
pDCs. The 30Gy irradiation provided to the pDC line induced a
strong activation of the cells as demonstrated by the upregulation
of costimulatory molecules (CD40, CD80, CD86), upregulation
of MHC-I molecules (Figure S6). In addition, by using IFNab
blocking antibodies, we observed that the induction of specific T
cell responses by the pDC line was not abrogated, suggesting a
type I IFN independent mechanism (Figure S7). We also
addressed the comparative avidity of the specific T cells elicited
by the pDC line or mDCs by measuring their cytotoxic activity
upon stimulation with titrated peptide-MHC complexes. We
observed that the specific T cells elicited by the pDCs kept the
same level of functionality towards T2 target cells loaded with up
to 0.01 mM whereas the specific T cells elicited by allogeneic
mDCs displayed a 50% reduced functionality at this peptide
concentration (Figure S8). Therefore, the pDCs elicited high
avidity specific T cells.
Discussion
pDCs can act as antigen presenting cells and they have been
demonstrated to play a role in tumor-specific responses [43].
However, the potential for pDCs in clinical application has not yet
been worked out. In this study, we explored the feasibility of
peptide-loaded HLA matched allogeneic pDC to induce tumor
immunity. We demonstrate here the strong potential of this
strategy in inducing multi-specific and highly functional CD8+ T
cell responses from healthy donors as well as cancer patients.
Figure 6. The melanoma patients’ tumor-specific T cells induced by the HLA-A*0201 matched allogeneic pDC line are highly
cytotoxic and lyse autologous melanoma tumor cells. Tumor-specific T cells induced by the pDC line loaded with melanoma-derived peptides
from melanoma patients’ PBMC and TIL are highly functional in an HLA-A*0201 and antigen-specific manner. (A) Tetramer
+ T cells specifically
secreted IFNc upon restimulation with T2 cells pulsed with the relevant peptide. Representative of 6 PBMC and 2 TIL samples. (B-D) T cells exhibited
cytotoxicity towards allogeneic and autologous melanoma tumor cells and relevant peptide-pulsed T2 cells. T cells induced from PBMC or TIL were
purified from days 15–20 cultures and used in a
51Cr release assay against peptide-loaded T2 cells, allogeneic and autologous melanoma tumor cells,
and autologous CD45
+ cells. (B) The PBMC sample shown was stimulated with MelA-loaded GEN cells. The TIL sample shown was stimulated with
GEN cells loaded with a mixture of 4 peptides and developed a response towards MelA, GP100 and MAGE-3 antigens (see Figure 5C). Representative
of 12 PBMC and 6 TIL samples. (C) Percentage of killing of autologous tumor cells compared to autologous CD45
+ cells by TIL before and after
stimulation. Representative of 6 TIL samples. (D) Comparison of the killing capacity between unstimulated and stimulated TIL on the indicated targets
at a 60:1 ratio. Mean+/-SEM of 6 TIL samples.
doi:10.1371/journal.pone.0010458.g006
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matched allogeneic pDCs as vectors for cancer immunotherapy.
The use of pDCs to induce T cell responses has already been
investigated in vitro and in mouse models of cancer and infection
[21,31], but its further development for clinical application was
impractical due to the absence of an easy way to generate or purify
human pDCs in sufficient number. As peptide-pulsed primary
pDCs isolated from the blood induced higher T cell responses in
HLA matched allogeneic settings compared to autologous
conditions, we further investigated the potential of pDC combined
with HLA matched allogeneicity using the HLA-A*0201
+ pDC
line. We demonstrated that the irradiated peptide-pulsed pDC line
can strongly trigger both primary and memory specific T cell
responses more effectively than conventional myeloid DCs. The
use of pDC in an allogeneic context with a partial HLA matching
between the vaccine and the responding T cells resulted in an
enhancement of HLA-A*0201-restricted specific responses, with
only minor allogeneic response induction as assessed by the low
level of non-specific T cell activation upon restimulation with the
vaccine. Thus, there is a strong enhancement induced by HLA
matched allogeneicity [37], that is further potentiated by a pDC
vaccineThe safety of allogeneic cell therapies has already been
Figure 7. The HLA-A*0201 matched allogeneic pDC line is more effective than conventional mDCs. PBMC from HLA-A*0201
+ healthy
donors were stimulated either with the pDC line or with allogeneic or autologous HLA-A*0201
+ mDCs loaded with Flu (A, B) or MelA (C, D) peptide in
presence of IL-2 where indicated. (A) Percentages of FluM1 tetramer
+ CD8+ T cells and (B) fold increase in specific T cell number at d7 of culture. MelA
tetramer was used as control. (C) Percentages of MelA tetramer
+ CD8+ T cells and (D) fold increase in specific T cell number at d20 of culture. Flu
tetramer was used as control.
doi:10.1371/journal.pone.0010458.g007
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strated in cancer patients that the use of HLA matched allogeneic
mDCs or mDCs/tumor hybrids induced strong anti-tumor
immune responses and clinical responses [47,48]. These studies
clearly demonstrate the feasibility of generation of tumor-specific
T cell responses in vivo on an allo-background. HLA-restricted
tumor specific T cell responses are not drowned out by bystander
alloresponses.
The use of HLA-matched allogeneic pDCs may explained the
relative important HLA-restricted responses over alloresponses
induction, and its efficacy. It has been shown that pDCs can
induce allogeneic T cell hyporesponsiveness and subsequent
prolonged graft survival [49]; this may be due to a high ratio of
B7-H1 to B7-1 and B7-2 molecule expression that in turn
influence the outcome of their interactions with T cells. It has also
been suggested that pDCs are equipped with large ‘‘ready-made’’
intracellular stores of MHC-I molecules than can be rapidly
mobilize to the cell surface to initiate antigen-specific CD8 T cell
responses [50]. The localization of MHC-I molecules in the
recycling endosomal compartment suggests a rapid translocation
to the cell surface after stimulation. In addition pDCs cross-present
antigens more rapidly and efficiently than do mDCs and this
process is IFNa-independent. In line with this, we observed a rapid
upregulation of MHC-I molecules on the peptide-loaded pDC line
upon activation and the induction of specific T cells was IFNa-
independent (not shown). These differences of MHC-I molecules
mobilization at early time points between pDCs and mDCs may
explain the superiority of pDCs over mDCs. In addition, pDCs
and mDCs handle MHC-II molecules differently after activation
[51]: pDCs continuously turn over MHC-II molecules after
activation whereas mDCs did not which results in sustained
surface expression of individual peptide-MHC-II molecules
complexes. pDCs display low amounts of MHC-II molecules on
their surface and did not upregulate MHC-II synthesis soon after
activation [52]. A possible explanation for the selective HLA
restricted- over allo-responses triggering by pDCs could be the
differential mobilization of MHC-I and MHC-II molecules upon
stimulation and the rapid mobilization of MHC-I molecules to the
cell surface. We observed that the specific T cell induction by the
pDCs was type I IFN independent (not shown). Furthermore, the
irradiation of the pDC line induced a strong cell activation as
assessed by the upregulation of the costimulatory markers CD40,
CD80, CD86 and HLA-A2 molecule and the secretion of pro-
inflammatory cytokines (not shown) to similar levels to the one
provided by TLR-7 or TLR-9 stimulation. On the contrary mDCs
did not upregulate these costimulatory molecules upon irradiation.
These unique features of pDCs could allow a preferential MHC-I
orientation leading to HLA restricted- over allo-responses
induction and contribute to its high HLA-A*0201 restricted
CD8 T cell stimulatory capacity.
Tumor-specific T cells induced by the HLA matched allogeneic
pDC were highly functional as demonstrated by the capacity of
tetramer
+ T cells to secrete IFNc and express CD107 upon specific
restimulation, and their strong antigen and HLA-A*0201-specific
cytotoxicity. As peptide-loaded T2 cells are more susceptible to
lysis than cells expressing the antigen endogenously, we performed
each cytotoxicity assay not only on peptide-loaded T2 cells, but
also on several allogeneic melanoma cell lines and importantly on
autologous melanoma tumor cells from the patients themselves.
Our results demonstrate that the specific T cells induced by the
pDC line are able to kill tumor cells expressing the antigen
endogenously. The phenotype of the effector T cells generated was
that of intermediate effectors: CD27+ CD45RO+ CD62L- T cells
(not shown), suggesting that they were not terminally differentiated
even after serial stimulations. Importantly, intermediate effector
cells have been indicated to be optimal for in vivo efficacy [53].
We also observed that the specific T cells elicited by the pDCs had
a better affinity and higher avidity compared to specific T cells
triggered by allogeneic mDCs, as suggested by a slowest tetramer
dissociation rate and a better functionality on titrated peptide-
MHC complexes (not shown). These observations suggest that the
specific T cells elicited by the pDC vaccine will be able to
recognize antigen at the physiological low concentrations. We also
demonstrated the strong potential of the peptide-loaded pDC line
to induce specific T cell responses in a humanized mouse model,
and its efficacy in inhibiting the development of already
established tumors.
Importantly, we further provide clinical relevance of this
strategy by demonstrating it potently stimulates highly functional
tumor-specific T cells from melanoma patients. After stimulation
with the pDC line loaded with a mix of four melanoma peptides, T
cells from melanoma patients acquired the ability to kill autologous
tumor cells. Such results were obtained with PBMC as well as with
TIL taken from all tested patients, at different stages of their
disease and regardless of their previous treatment, providing the
preclinical evidence for the strong potential of our strategy.
We performed a comparison of our strategy with frequently
used myeloid derived dendritic cells. As demonstrated for several
antigens and with healthy donors’ as well as melanoma patients’
cells, the pDC line led to a more potent induction of tumor-specific
T cells endowed with better functional capacities compared to
conventional mDCs. CTL generated by the pDC line are much
more effective in killing autologous melanoma tumor cells
compared to CTL generated by mDC. Allogeneic leukaemic
myeloid cell lines that have DC properties have also been
evaluated for their potential to prime tumor-specific CTL [54,55],
but our strategy is superior in many aspects including the cell line
generation, the settings required for induction of T cell responses,
and the efficacy of specific T cells elicited.
The efficacy and design of this immunotherapeutic approach
render the strategy very attractive for further clinical develop-
ments. Our peptide-pulsed pDC line can be provided directly as a
ready-to-use GMP secured frozen vaccine. Notably, it represents a
multi-usage flexible strategy, as the same vaccine can be used for
every HLA-A*0201
+ patient, and by utilizing target antigens it can
be suitable for various pathologies. Regarding clinical use, we have
already addressed a number of biosafety issues, in accordance with
regulatory requirements.
This work demonstrates that HLA matched allogeneic pDCs
are promising vectors for cancer immunotherapy. GENiusVac
represents a real advancement in the challenging area of cancer
immunotherapy with broad clinical applications.
Figure 8. The HLA-A*0201 matched allogeneic pDCs are more potent at inducing tumor-specific T cells from melanoma patients
than conventional mDCs. TIL from melanoma patients were cultured either with irradiated GEN cells or allogeneic LPS-matured HLA-A*0201
+
mDCs loaded with a mixture of MelA, GP100, TYR and MAGE-3 derived peptides. Percentages of tumor-specific T cells were determined by tetramer
labelling after three stimulations at day 20 of culture. (A) Representative dotplots of two cultures. (B) Comparative percentages of MelA-specific T cells
and (C) fold increase in specific T cell numbers upon stimulation of TIL with GEN or mDCs (4 patients). (D,E) T cells were purified from the culture and
submitted to a
51Cr release assay. (D) Percentage of killing of autologous tumor cells and autologous CD45
+ cells after TIL stimulation with GEN or
mDCs. One representative patient is shown. (E) Comparative killing efficacy against autologous tumor cells at a 60:1 ratio.
doi:10.1371/journal.pone.0010458.g008
pDC-Based Cancer Vaccine
PLoS ONE | www.plosone.org 14 May 2010 | Volume 5 | Issue 5 | e10458Supporting Information
Figure S1 HLA-A2 and tumor antigen expression by melanoma
tumor cell lines. (A) Analysis by flow cytometry of surface HLA-A2
(top panels) and intracellular MelA (lower panels) expression by
Me275, Mel89, COLO829 and A375 melanoma tumor cell lines.
(B) Analysis by real time PCR of MelA, GP100, tyrosinase and
MAGE-3 gene expression by Me275, Mel89, COLO829 and
A375 melanoma tumor cell lines.
Found at: doi:10.1371/journal.pone.0010458.s001 (4.76 MB TIF)
Figure S2 The HLA-A*0201 matched allogeneic pDC line
induces highly effective virus-specific T cell responses from HLA-
A*0201
+ healthy donors’ PBMC in vitro. Allogeneic HLA-A*0201
PBMC from healthy donors were stimulated with the irradiated
peptide-loaded HLA-A*0201
+pDC line. Specificity of the T cells was
determined by tetramer labelling and flow cytometric analysis. (A)
Representative dot plot of Flu M1 tetramer labelling at d0 and d7 of
culture (gated on CD8+ T cells). (B) Percentages of Flu M1 tetramer
+
CD8+ T cells determined at d0 and d7 of culture (n=20). (C)
Representative dot plot of CMVpp65 tetramer labelling at d0 and d7
of culture (gated on CD8+ T cells). (D) Percentages of CMV pp65
tetramer
+ CD8+ T cells determined at d0 and d7 of culture (n=14).
Anti-viral tetramer
+ T cell responses reached averages of 11% for
FluM1 (range 0.1–49) and 12% for CMVpp65 (range 0.04–76) in 7
days starting from respectively 0.23 and 0.18%.
Found at: doi:10.1371/journal.pone.0010458.s002 (5.25 MB TIF)
Figure S3 The virus-specific T cells induced in vitro by the
HLA-A*0201 matched allogeneic pDC line exhibited functional
HLA-A*0201- and antigen-specific activity. (A) Flu-specific T cells
induced by the pDC line secrete IFNc and express CD107 on the
surface upon restimulation. Cells from the culture (day 8) were
tetramer labeled and restimulated with T2 cells pulsed with a
relevant or control peptide. IFNc production was assessed by
intracellular staining and CD107 expression by adding anti-
CD107a+b antibodies during the restimulation. Dotplots are gated
on tetramer
+ CD8+ T cells. Representative of 4 experiments
performed with 3 donors at day 8-10 of the culture. (B) Flu-specific
T cells induced by the pDC line are cytotoxic. T cells were selected
from the culture and submitted to a
51Cr release assay using
peptide-loaded T2 cells as targets. T cells killed T2 cells loaded
with the relevant but not the control peptide. Representative of 7
experiments performed with 4 donors at d7-10 of the culture.
(C,D) IFNc secretion and CD107 expression were assessed as
described in (A) after a single stimulation of PBMC and analyzed
on the tetramer
+ CD8+ T cells (white bars) and on the non-specific
tetramer
- CD8+ T cells (grey bars) and CD4+ T cells (black bars)
upon restimulation with peptide-pulsed T2 or GEN cells (4
experiments for each condition).
Found at: doi:10.1371/journal.pone.0010458.s003 (4.90 MB TIF)
Figure S4 Response kinetics to vaccination with peptide-loaded
GEN cells in humanized mice. Immunodeficient NOD-SCID
b2m
-/- mice were reconstituted intraperitoneally with 50.10
6
human HLA-A*0201 PBMC and weekly vaccinated by the same
route with 5.10
6 irradiated peptide-loaded GEN cells. Specific T
cell induction was analyzed at different timepoints after vaccina-
tion at the injection site (lavage), in the circulation (blood) and
lymphoid organs (spleen, MLN) by tetramer labelling of human T
cells in cell suspensions. (A) Tumor-specific response to MelA-
loaded GEN vaccination and (B) virus-specific response to Flu-
loaded GEN vaccination. Each dot represents one vaccinated
HuPBL mice.
Found at: doi:10.1371/journal.pone.0010458.s004 (4.64 MB TIF)
Figure S5 TYR-specific T cells induction. Percentage of TYR-
specific T cells determined at different timepoints of the PBMC
culture from a melanoma patient (#4) with TYR-loaded GEN
cells (gated on CD8+ T cells).
Found at: doi:10.1371/journal.pone.0010458.s005 (4.49 MB TIF)
Figure S6 The 30Gy irradiation induced activation of the pDC
line. pDCs were either untreated or submitted to a 30Gy
irradiation. Twenty four hours later, the expression of costimu-
latory and HLA-A2 molecules were analysed by flow cytometry
(representative of three experiments).
Found at: doi:10.1371/journal.pone.0010458.s006 (4.38 MB TIF)
Figure S7 The induction of specific T cells by the pDC line is
type I IFN independent. Allogeneic HLA-A*0201
+ PBMC from
healthy donors were stimulated with the irradiated Flu- or MelA-
peptide loaded HLA-A*0201
+ pDC line in the presence of anti-
IFNa and anti-IFNb antibodies or control goat IgG. The level of
specific T cells was determined at day 7 of the culture by tetramer
labelling and flow cytometry analysis.
Found at: doi:10.1371/journal.pone.0010458.s007 (4.21 MB TIF)
Figure S8 Comparative avidity of the specific T cells elicited by
the pDC line and allogeneic mDCs. Allogeneic HLA-A*0201
+
PBMC from healthy donors were stimulated with the irradiated
Flu-peptide loaded HLA-A*0201
+ pDC line or HLA-A*0201
+
mDC. At day 7 of the culture, the cytotoxic activity of the specific
T cells was evaluated by a
51Cr release assay on T2 cells loaded
with decreasing concentrations of Flu peptide (1 mM to 0.0001
mM), irrelevant peptide or unloaded. Data are expressed as a
percentage of the maximum lysis measured for a E:T ratio of 30:1.
Found at: doi:10.1371/journal.pone.0010458.s008 (4.21 MB TIF)
Table S1 Melanoma patients’ samples and clinical parameters
description.
Found at: doi:10.1371/journal.pone.0010458.s009 (4.57 MB TIF)
Table S2 Initial levels of tetramer
+ CD8 T cells within
melanoma patients’ samples.
Found at: doi:10.1371/journal.pone.0010458.s010 (4.57 MB TIF)
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